This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Risnes, I Articles by Svennevig, J. Search for Related Content PubMed PubMed Citation Articles by Risnes, I Articles by Svennevig, J. Social Bookmarking                   What's this?

Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment

Department of Thoracic and Cardiovascular Surgery, Rikshospitalet-University of Oslo, Oslo, Norway ivar.risnes{at}rikshospitalet.no

K Wagner

Department of Anaesthesiology, Rikshospitalet-University of Oslo, Oslo, Norway

T Ueland

Research Institute for Internal Medicine, Rikshospitalet-University of Oslo, Oslo, Norway; Section of Endocrinolgy, Rikshospitalet-University of Oslo, Oslo, Norway

TE Mollnes

Institute of Immunology, Rikshospitalet-University of Oslo, Oslo, Norway

P Aukrust

Research Institute for Internal Medicine, Rikshospitalet-University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Rikshospitalet-University of Oslo, Oslo, Norway

JL Svennevig

Department of Thoracic and Cardiovascular Surgery, Rikshospitalet-University of Oslo, Oslo, Norway

The cytokine network and its association with complement activation during cardiac surgery with cardiopulmonary bypass (CPB) is complex. Extracorporeal membrane oxygenation (ECMO) differs from CPB in duration of days to weeks rather than hours. However, few studies have analyzed the levels of inflammatory mediators during ECMO treatment. Plasma samples from 22 patients [nine neonates, one infant, four children and eight adults (14 males and eight female)] who underwent ECMO treatment were collected prior to, during and after treatment, and analyzed for concentrations of inflammatory and anti-inflammatory cytokines and parameters of complement activation. Seven children were treated for cardiac and seven for pulmonary failure and, in the adult group, four were treated for cardiac and four for pulmonary failure. ECMO was performed with veno-arterial (VA) bypass in all children and five adults, and with veno-venous (VV) bypass in three adults. Fourteen patients survived (64%) and eight (36%) patients died during follow-up. A marked (~99%) and rapid (i.e., within two days) decrease in IL-6 was seen in survivors. The non-survivors were characterized by persistently high IL-6 levels throughout the observation period (i.e., until death). C-reactive protein (CRP) levels showed a similar pattern as the IL-6, with higher levels in non-survivors throughout the observation period. However, in contrast to IL-6, the differences between survivors and non-survivors reached statistical significance, but only at the end of the observation period. It is possible that early measurements of IL-6 in ECMO patients could give prognostic information beyond that of CRP.

Key Words: complement • cytokines • inflammation

Perfusion, Vol. 23, No. 3, 173-178 (2008)
DOI: 10.1177/0267659108097882


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?